Study visits | V0 | V1 | V8 | p valuea | p valuea | p valueb |
---|---|---|---|---|---|---|
(139) | (139) | (139) | V0xV1 | V1x V8 | V0xV1xV8 | |
FVC L | 2.7 (2.3–3.5) | 2.8 (2.3–3.4) | 2.6 (2.1–3.1) | 0.98 | <0.01 | 0.00 |
FVC (% pred) | 91.0 (77.0–101.0) | 91.0(79.0–102.0) | 82.2 (73.6–92.0) | 0.43 | <0.01 | 0.00 |
FEV1 (L) | 1.9 (1.4–2.3) | 1.9 (1.5–2.4) | 1.7 (1.3–2.2) | 0.41 | <0.01 | 0.00 |
FEV1 (%pred) | 73.0 (60.0–85.0) | 73.0 (63.0–86.0) | 67.2 (56.3–80.3) | 0.15 | <0.01 | 0.00 |
FEV1/FVC | 0.7 (0.6–0.8) | 0.7 (0.6–0.8) | 0.7 (0.6–0.7) | 0.34 | 0.21 | 0.47 |
FEV1/FVC (%pred) | 82.0 (68.0–93.0) | 83.0 (71.0–92.0) | 81.5 (74.7–91.4) | 0.23 | 0.41 | 0.18 |
FEF25–75% (L/s) | 1.0 (0.6–1.6) | 1.1 (0.6–1.8) | 1.0 (0.7–1.6) | 0.04 | <0.01 | 0.05 |
FEF25–75% (%pred) | 34.0 (22.0–57.0) | 41.0 (25.0–64.0) | 37.8 (29.9–62.7) | 0.04 | 0.88 | 0.05 |
BD chg (ml) | 290.0(180.0–440.0) | 160.0(40.0–340.0) | 170.0(70.0–300.0) | <0.01 | 0.87 | 0.00 |
BD chg (%) | 18.0 (11.0–28.0) | 10.0 (2.0–22.0) | 11.6 (5.0–20.7) | <0.01 | 0.10 | 0.00 |